Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Auto-HSCT plus ablation in severe scleroderma
Sullivan KM et al. ACR Annual Meeting, Abstract 1820
Key clinical point: Treating severe scleroderma patients with myeloablation and autologous stem cell transplantation had durable efficacy and safety out to 11 years.
Major finding: Survival after 11 years was 88% among transplanted patients and 53% among control patients treated with cyclophosphamide.
Study details: A long-term follow-up of 43 of the 75 patients enrolled in the SCOT trial.
Disclosures: SCOT received no commercial funding. Dr. Sullivan had no disclosures to report.
Citation:
Sullivan KM et al. ACR Annual Meeting, Abstract 1820
